PlainPharmaWatch

CMS Open Payments · Tool

Limacorporate S.p.A. vs UCB Biosciences Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

UCB Biosciences Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 7,541, versus 995 for the other company. Its single largest recorded recipient represents 86.1% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Limacorporate S.p.A.
HHI 995 · top recipient 18.9%
Ranked #1,032 of 1,838 companies by HHI
UCB Biosciences Inc.
HHI 7,541 · top recipient 86.1%
Ranked #206 of 1,838 companies by HHI

Payment Overview

Total Payments
$343.6K
% of Industry
0.0%
Transactions
161
Avg per Transaction
$2.1K
Recipients
119
Avg per Recipient
$2.9K
Payment Types
4
Top Payment Type
Consulting Fee
Total Payments
$337.8K
% of Industry
0.0%
Transactions
20
Avg per Transaction
$16.9K
Recipients
13
Avg per Recipient
$26.0K
Payment Types
2
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Limacorporate S.p.A. vs UCB Biosciences Inc. - total reported payments in CMS Open Payments PY2024

Limacorporate S.p.A.$343.6KUCB Biosciences Inc.$337.8K

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Limacorporate S.p.A.

Consulting Fee $123.7K

67.3%

Royalty or License $36.6K

19.9%

Travel and Lodging $21.7K

11.8%

Food and Beverage $1.8K

1.0%

UCB Biosciences Inc.

Consulting Fee $16.5K

99.0%

Food and Beverage $167.78

1.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Limacorporate S.p.A.

  1. 1

    BENJAMIN STRONACH

    $34,755.10 · 8 txns

  2. 2

    SETH GREENKY

    $25,000.00 · 8 txns

  3. 3

    PATRICK CONNOR

    $16,661.47 · 2 txns

  4. 4

    ANIL DUTTA

    $15,594.40 · 15 txns

  5. 5

    CRAIG CUMMINS

    $15,275.00 · 4 txns

UCB Biosciences Inc.

  1. 1

    PIERRE C WONG

    $14,350.00 · 10 txns

  2. 2

    JAMI C LEVINE

    $1,920.00 · 1 txns

  3. 3

    DAVID M HARRILD

    $237.50 · 1 txns

  4. 4

    JEFFREY L BENNETT

    $167.78 · 1 txns

Summary Comparison

Metric Limacorporate S.p.A. UCB Biosciences Inc.
Total Payments $343.6K $337.8K
% of Industry Total 0.0% 0.0%
Transaction Count 161 20
Avg per Transaction $2.1K $16.9K
Recipient Count 119 13
Avg per Recipient $2.9K $26.0K
Payment Type Count 4 2
Top Payment Type Consulting Fee Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.